Still In Development
Last Update: September 04, 2011
PATH is now piloting the use of oxytocin in Uniject syringes in order to combat post-partum hemorrhage.
Trials among community health workers in Latin America and Africa will be evaluated in hopes of introducing this technology on a larger scale.
The Uniject device is a pre-filled one-time use syringe developed by PATH. A pre-filled, pre-dosed vaccine enables untrained health workers to give life-saving vaccines without wastage, mis-dosing and spread of infection (because the syringe is used only once). Currently this device is available pre-filled with hepatitis B vaccine or tetanus toxoid. The device is being field-tested for use with other medications, such as gentamicin, which is used to treat life-threatening infections in infants.
